| 0 | ℹ |
Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial.
(academic.oup.com)
|
Clinical Infectious Diseases 2026-09-21 | #rabies #immunotherapy #prophylaxis #vaccination #antibody |